With every passing day, new discoveries are made that lend support to the increasing and important role biomarker analysis and tumor profiling play in personalized cancer care. Caris Life Sciences® is actively participating in research to advance the understanding of molecular science, further enabling the delivery of precision medicine.

ASH 2017-ADAPT-Aptamer C10.36 Reveals a Ribonucleoprotein Complex on the Surface of Non-Hodgkin Lymphoma Cells Providing Candidates for Multi-Target Therapeutics

Polyligand profiling differentiates breast cancer patients according to their benefit from trastuzumab treatment

Poly-ligand profiling and target identification from formalin-fixed-paraffin embedded HER2+ breast cancer specimens

Distribution of microsatellite instability (MSI), tumor mutational load (TML) and PD-L1 status in molecularly profiled invasive breast cancer

Comparison of progression-free survival (PFS) on comprehensive multiplatform profiling-guided therapy to PFS on prior therapy-

Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy

High-Intermediate Risk Endometrial Cancer: Can Gene Expression Predict Recurrence?

Molecular Profiling for Clinical Decision Making in Advanced Cancer: A Clinical Appraisal

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy

Identification of molecular targets in vulvar cancers